NCT02182050View on ClinicalTrials.gov

Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2007

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

BIBF 1120 ES low dose

DRUG

BIBF 1120 ES high dose

DRUG

Placebo to BIBF 1120 ES

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY